Medication vs Therapy: What the Research Actually Shows (2026)

Key Takeaways

• Short-term outcomes are comparable. For depression and most anxiety disorders, SSRIs and evidence-based therapy (particularly CBT) produce similar response rates over 8 to 16 weeks.
• Therapy has a long-term edge. After treatment ends, therapy patients maintain gains better than those who discontinue medication, with relapse rates roughly half as high.
• Combined treatment outperforms monotherapy. For moderate-to-severe depression, combining medication and therapy improves response rates by 20 to 30 percent over either alone.
• For PTSD, therapy is the clear first-line choice. Trauma-focused therapies outperform SSRIs, and every major clinical guideline recommends therapy as the primary treatment.
• Neither option is universally "better." The right choice depends on condition severity, patient preference, access, and individual biology.

The Short Answer

The medication-versus-therapy debate is one of the most researched questions in mental health. After decades of head-to-head trials involving hundreds of thousands of patients, the evidence points to a consistent pattern:

1. Acute treatment: Medication and evidence-based psychotherapy produce roughly equivalent results for depression and anxiety over 2 to 4 months.
2. Long-term maintenance: Psychotherapy provides more durable protection against relapse after treatment ends.
3. Combined treatment: Using both together tends to outperform either one alone, particularly for moderate-to-severe conditions.

These are averages across large populations. Individual responses vary considerably based on diagnosis, severity, personal history, and biology. For a broader look at the factors that go into this decision, see our guide on therapy vs medication.

---

Depression: SSRIs vs CBT

Depression has more head-to-head medication-versus-therapy data than any other condition. The findings are remarkably consistent.

Acute Treatment (8-16 Weeks)

~60-65%

Source: Cuijpers et al., World Psychiatry, 2020

Multiple large-scale studies have compared SSRIs directly against cognitive behavioral therapy:

• DeRubeis et al. (2005) randomized 240 patients with moderate-to-severe depression to paroxetine, CBT, or placebo. At 8 weeks, response rates were 50% for medication and 43% for CBT -- a non-significant difference. By 16 weeks, both reached approximately 58% (JAMA, 2005).
• Cuijpers et al. (2020) conducted a comprehensive meta-analysis of 101 studies comparing psychotherapy to pharmacotherapy for depression. The overall effect size difference was d = 0.07 in favor of medication -- statistically and clinically negligible (World Psychiatry, 2020).
• Weitz et al. (2015) found in a patient-level meta-analysis that CBT and antidepressants performed equivalently across severity levels, including severe depression (Clinical Psychology Review, 2015).

Long-Term Outcomes and Relapse

This is where the data diverges significantly.

2x

Source: Hollon et al., Archives of General Psychiatry, 2005

• Hollon et al. (2005) followed patients for 12 months after treatment. Among medication responders who discontinued their SSRI, 76% relapsed. Among CBT responders, only 31% relapsed -- comparable to those who continued medication (Archives of General Psychiatry, 2005).
• Vittengl et al. (2007) conducted a meta-analysis of 28 studies and found the relapse rate after CBT was 29%, versus 54% after medication discontinuation (Journal of Consulting and Clinical Psychology, 2007).
• Cuijpers et al. (2013) found that the protective effect of CBT against relapse persisted for at least 2 years post-treatment (Clinical Psychology Review, 2013).

The explanation most supported by research is that therapy teaches skills -- cognitive restructuring, behavioral activation, problem-solving -- that patients retain after treatment ends. Medication treats symptoms while it is being taken but does not change the underlying cognitive patterns.

Combined Treatment for Depression

20-30%

Source: Cuijpers et al., World Psychiatry, 2014

• Cuijpers et al. (2014) meta-analyzed 52 studies and found a combined effect size of d = 0.43 for combination over medication alone and d = 0.35 over therapy alone (World Psychiatry, 2014).
• Keller et al. (2000) -- the landmark CBASP study -- found that for chronic depression, the combination of nefazodone and CBASP (a therapy designed for chronic depression) yielded a 73% response rate versus 48% for medication alone and 48% for therapy alone (New England Journal of Medicine, 2000).
• The STAR*D trial found that patients who did not respond to initial SSRI treatment showed improved outcomes when CBT was added as an augmentation strategy, with remission rates comparable to medication switches (American Journal of Psychiatry, 2007).

---

Anxiety Disorders: SSRIs vs CBT

The anxiety disorder literature follows a pattern similar to depression, with some important nuances by diagnosis.

Generalized Anxiety Disorder (GAD)

• Cuijpers et al. (2014) found that CBT and pharmacotherapy (SSRIs/SNRIs) produced comparable effect sizes for GAD, with d = 0.01 difference between them -- essentially identical outcomes (Clinical Psychology Review, 2014).
• Bandelow et al. (2015) found effect sizes of d = 0.50 for CBT and d = 0.45 for SSRIs compared to placebo for GAD -- no significant difference (World Journal of Biological Psychiatry, 2015).

Social Anxiety Disorder

• Mayo-Wilson et al. (2014) conducted a network meta-analysis of 101 trials for social anxiety. Individual CBT (d = 1.19) outperformed SSRIs (d = 0.91) in direct comparisons, though both were substantially better than placebo (The Lancet Psychiatry, 2014).
• Leichsenring et al. (2013) found that CBT produced significantly lower relapse rates than sertraline after treatment discontinuation for social anxiety (JAMA Psychiatry, 2013).

Panic Disorder

• Furukawa et al. (2007) meta-analyzed 21 trials and found CBT slightly outperformed antidepressants at post-treatment for panic disorder, with a more pronounced advantage at follow-up (Psychological Medicine, 2007).
• Barlow et al. (2000) -- one of the most cited studies -- found that CBT alone was as effective as imipramine acutely, and superior at 6-month follow-up after treatment discontinuation (JAMA, 2000).

---

PTSD: Therapy Clearly Outperforms Medication

PTSD is the condition where the evidence most clearly favors psychotherapy over medication.

Therapy recommended over medication

Source: APA Clinical Practice Guideline, 2017

Head-to-Head Data

• Watts et al. (2013) conducted a comprehensive meta-analysis and found trauma-focused therapies (CPT, Prolonged Exposure, EMDR) produced effect sizes of d = 1.14 to 1.26, versus d = 0.42 for SSRIs (Journal of Clinical Psychiatry, 2013).
• The landmark Resick et al. (2017) study compared sertraline to CPT head-to-head and found CPT produced significantly greater PTSD symptom reduction. Loss of PTSD diagnosis occurred in 53% of CPT patients versus 42% of sertraline patients (JAMA, 2017).
• Schnurr et al. (2007) found Prolonged Exposure produced larger symptom reductions than sertraline in female veterans (JAMA, 2007).

Why Therapy Wins for PTSD

The mechanism matters. Trauma-focused therapies work by processing the traumatic memory itself -- helping the brain re-categorize and integrate the experience. SSRIs manage symptoms (hyperarousal, mood, sleep) but do not address the underlying trauma processing deficit. This is why guideline panels consistently recommend therapy as the primary treatment, with SSRIs as a second-line or adjunctive option.

For a deeper dive into how trauma-focused approaches compare to each other, see our guides on CPT vs EMDR, EMDR vs Prolonged Exposure, and our trauma condition page.

---

OCD: ERP and SSRIs Both Work, Together is Best

OCD presents a slightly different picture. Both Exposure and Response Prevention (ERP) and SSRIs have strong evidence, and the combination has a clear advantage.

ERP: d = 1.13 | SSRIs: d = 0.91

Source: Ost et al., Clinical Psychology Review, 2015

Monotherapy Comparison

• Foa et al. (2005) randomized 122 OCD patients to ERP, clomipramine, ERP + clomipramine, or placebo. ERP alone produced the highest response rate at 86%, versus 48% for clomipramine alone and 79% for the combination (American Journal of Psychiatry, 2005).
• Ost et al. (2015) meta-analyzed 37 RCTs and found ERP slightly outperformed SSRIs as monotherapy, with effect sizes of d = 1.13 for ERP versus d = 0.91 for SSRIs (Clinical Psychology Review, 2015).

Combined Treatment

• Simpson et al. (2008) found that adding ERP to SSRI treatment for partial responders produced significantly greater improvement than adding stress management training. The ERP augmentation group showed a 52% mean reduction in OCD symptoms versus 11% in the control group (JAMA, 2008).
• For patients already on an SSRI with partial response, adding ERP is the most evidence-based next step -- more effective than SSRI dose increases or SSRI switches (Bloch et al., Molecular Psychiatry, 2006).

---

Side Effects: A Head-to-Head Comparison

Side effects are a critical and often underweighted factor in treatment decisions. Both medication and therapy carry risks, but they are qualitatively different.

Medication Side Effects

SSRIs and SNRIs -- the most commonly prescribed medications for depression and anxiety -- carry well-documented side effects:

Sources: Cascade et al., Psychiatry, 2009; Read & Williams, Addictive Behaviors, 2018; Bet et al., Journal of Clinical Psychiatry, 2013; Fava et al., Psychotherapy and Psychosomatics, 2015.

Therapy Side Effects

Therapy is not side-effect-free, but the adverse effects are generally milder and transient:

• Temporary emotional distress. Up to 50% of patients report feeling temporarily worse after difficult sessions, particularly in trauma-focused work. This typically resolves within 24 to 48 hours (Linden, World Psychiatry, 2013).
• Time commitment. Weekly sessions of 45 to 60 minutes, plus homework between sessions, represent a significant practical burden for some patients.
• Financial cost. Without insurance, therapy sessions range from $100 to $300. See our therapy cost guide for details.
• Rare negative effects. In approximately 5 to 10 percent of cases, patients report therapy was unhelpful or made them worse, often due to poor therapeutic fit or inappropriate treatment selection (Crawford et al., British Journal of Psychiatry, 2016).

---

Relapse Rates After Treatment Ends

One of the strongest arguments for including therapy in a treatment plan is the durability of its effects.

40-60% vs 20-30%

Source: Vittengl et al., 2007; Hollon et al., 2005; Batelaan et al., 2017

Depression Relapse

• After SSRI discontinuation: 40 to 60 percent relapse within 6 to 12 months (Geddes et al., The Lancet, 2003).
• After completing CBT: 20 to 35 percent relapse over the same period (Vittengl et al., Journal of Consulting and Clinical Psychology, 2007).
• With continued maintenance medication: 20 to 30 percent relapse -- similar to post-CBT rates, but requires ongoing medication (Geddes et al., The Lancet, 2003).

Anxiety Relapse

• After benzodiazepine discontinuation: 60 to 80 percent return of symptoms (Rickels et al., Archives of General Psychiatry, 1993).
• After SSRI discontinuation: 30 to 60 percent relapse (Batelaan et al., JAMA Psychiatry, 2017).
• After completing CBT for anxiety: 10 to 25 percent relapse (Batelaan et al., JAMA Psychiatry, 2017).

The Maintenance Medication Question

For patients who respond well to medication, the alternative to discontinuation is long-term maintenance treatment. Maintenance medication does reduce relapse -- to rates comparable to post-therapy levels. However, this means indefinite medication use, with the cumulative side effect burden that entails. This is why many clinicians recommend that patients who start with medication also complete a course of therapy, giving them the skills to eventually taper medication with lower relapse risk.

---

Cost-Effectiveness Over Time

The cost comparison between medication and therapy is more nuanced than it first appears.

• Ophuis et al. (2017) found that CBT was cost-effective relative to antidepressants over a 5-year horizon when accounting for relapse costs and quality-adjusted life years (JAMA Psychiatry, 2017).
• Grosse Holtforth et al. (2019) concluded that while therapy has higher upfront costs, the total cost of care over 2 to 5 years is comparable or lower due to reduced relapse and lower indirect costs.
• The UK's NICE guidelines have consistently endorsed CBT as a cost-effective first-line treatment, partly because of the lower long-term costs associated with reduced relapse.

---

Combined Treatment: The Best of Both

For many patients -- particularly those with moderate-to-severe symptoms -- the evidence supports combining medication and therapy rather than choosing one.

Key Combined Treatment Studies

Depression:

• The CBASP study (Keller et al., 2000): Combined nefazodone + therapy achieved 73% response versus 48% for either monotherapy.
• Cuijpers et al. (2014) meta-analysis: Combined treatment was significantly superior to medication alone (d = 0.43) and therapy alone (d = 0.35).

Anxiety:

• Foa et al. (1999): For social anxiety, combined sertraline + exposure therapy outperformed either alone.
• Barlow et al. (2000): For panic disorder, combined CBT + imipramine showed the highest acute response rates, though CBT alone was superior at follow-up after medication discontinuation.

OCD:

• Simpson et al. (2008): Adding ERP to partial SSRI responders produced 52% symptom reduction versus 11% with stress management.

PTSD:

• Combination data is mixed for PTSD. Adding sertraline to Prolonged Exposure does not consistently improve outcomes, reinforcing that therapy is the active ingredient for trauma processing.

---

What This Means for You

The research is clear: medication and therapy are both legitimate, evidence-based treatments. Neither is inherently superior. The choice depends on your specific situation.

Factors Favoring Starting with Therapy

• You have mild-to-moderate symptoms
• You prefer to avoid medication side effects
• You want long-term relapse prevention
• You have a condition where therapy has a clear edge (PTSD, specific phobias, OCD)
• You have access to a therapist trained in evidence-based approaches

Factors Favoring Starting with Medication

• You have severe symptoms that make it hard to engage in therapy
• You need faster symptom relief (medication can work in 2 to 4 weeks; therapy typically takes 6 to 8 weeks to show significant effects)
• You have limited access to evidence-based therapy
• You have responded well to medication in the past
• You have biological features (e.g., strong family history, melancholic features) associated with medication response

Factors Favoring Combined Treatment

• Moderate-to-severe depression
• Chronic depression (over 2 years)
• Partial response to initial monotherapy
• OCD with incomplete SSRI response
• High relapse risk

For help finding the right provider to guide this decision, see our guides on how to find the best therapist and questions to ask a therapist.

---

Frequently Asked Questions

---